ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: GlobeNewswire
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney’s commercial strategy as the Company advances towards the potential commercialization of rilparencel. “Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market,” said Bruce Culleton, M.D., CEO of ProKidney. “He brings valuable operational and leadership skills needed to help guide ProKidney through its next phase of growth, including strong depth in nephrology and other specialty markets. As we advance our clinical and regulatory objectives for rilparencel, Greg will play a key role in strengthening our leadership team and posit
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney (PROK) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PROK&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "seMarketBeat
- ProKidney (PROK) was upgraded by Jefferies Financial Group Inc. to "strong-buy".MarketBeat
- ProKidney GAAP EPS of -$0.52 beats by $0.18, revenue of $0.89M beats by $0.35M [Seeking Alpha]Seeking Alpha
- ProKidney Reports Full Year 2025 Financial Results and Business HighlightsGlobeNewswire
- ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably [Seeking Alpha]Seeking Alpha
PROK
Earnings
- 3/18/26 - Miss
PROK
Sec Filings
- 3/18/26 - Form S-8
- 3/18/26 - Form 8-K
- 3/18/26 - Form 10-K
- PROK's page on the SEC website